
    
      To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen
      in hormone receptor positive, HER2 negative metastatic breast cancer patients who have
      progressed after prior endocrine treatment .Description of toxicity profile, severity and
      frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To
      evaluate the safety and tolerability of GDC-0032 in combination with tamoxifen, recording
      adverse events using CTCAE v. 4.0 criteria To describe the pharmacokinetics of GDC-0032 in
      combination with tamoxifen To investigate the possibility of major drug-drug interactions
      (PK) To obtain proof of target inhibition by selected pharmacodynamic measurements To look
      for preliminary evidence of anti-tumour activity To assess the status of potential biomarkers
      for drug response like PIK3CA gene mutations, relevant proteins and phospho-proteins in the
      PI3K pathway, circulating tumour DNA (ct-DNA) To assess germline DNA sequence for
      pharmacogenetics studies
    
  